This is not the most recent version of the article. View current version (31 MAR 2015)

Intervention Protocol

You have free access to this content

Buprenorphine for treating cancer pain

  1. Mia Schmidt-Hansen1,*,
  2. Nathan Bromham1,
  3. Mark Taubert2,
  4. Stephanie Arnold1

Editorial Group: Cochrane Pain, Palliative and Supportive Care Group

Published Online: 10 DEC 2013

DOI: 10.1002/14651858.CD009596.pub3

How to Cite

Schmidt-Hansen M, Bromham N, Taubert M, Arnold S. Buprenorphine for treating cancer pain (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD009596. DOI: 10.1002/14651858.CD009596.pub3.

Author Information

  1. 1

    National Collaborating Centre for Cancer, Cardiff, UK

  2. 2

    Velindre Cancer Centre, Cardiff, UK

*Mia Schmidt-Hansen, National Collaborating Centre for Cancer, 2nd Floor, Park House, Greyfriars Road., Cardiff, CF10 3AF, UK.

Publication History

  1. Publication Status: Amended to reflect a change in scope (see 'What's new')
  2. Published Online: 10 DEC 2013


This is not the most recent version of the article. View current version (31 MAR 2015)


Additional references

  1. Additional references
  2. References to other published versions of this review
Bach 1991
  • Bach V, Kamp-Jensen M, Jensen NH, Eriksen J. Buprenorphine and sustained release morphine - Effect and side-effects in chronic use. Pain Clinic 1991;4:87-93.
Bennett 2008
  • Bennett MI. What evidence do we have that the WHO analgesic ladder is effective in cancer pain?. In: McQuay HJ, Moore R, Kalso E editor(s). Systematic Reviews in Pain Research; Methodology Refined. Seattle: IASP Press, 2008:303-13.
Budd 2004
  • Budd K, Shipton E. Acute pain and the immune system and opioimmunosuppression. Acute Pain 2004;6:123-35.
Bullingham 1981
Bullingham 1983
Dahan 2005
  • Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. British Journal of Anaesthesia 2005;94:825-34.
Dahan 2006
  • Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. British Journal of Anaesthetics 2006;96:627-32.
Deandra 2008
Elkader 2005
Filitz 2006
Foley 1998
  • Foley KM. Pain assessment and cancer pain syndromes. In: Doyle D, Hanks GWC, MacDonald N editor(s). Oxford textbook of palliative medicine. Oxford: Oxford University Press, 1998:310-31.
Foster 2013
Gal 1989
  • Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression. Clinical Pharmacology and Therapeutics 1989;45:6-71.
Hadley 2013
Hand 1990
  • Hand CW, Sear JW, Uppington J, Ball MJ, McQuay HJ, Moore RA. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. British Journal of Anaesthesia 1990;64:276-82.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from
Likar 2008
Mercadante 2009
Moore 2013
NICE 2012
  • National Institute for Health and Care Excellence. Opioids in palliative care. Clinical guidelines CG140. Issued: May 2012. Available from
Nicholson 2007
Pace 2007
  • Pace MC, Passavanti MB, Grella E, Mazzariello L, Maisto M, Barbarisi M, et al. Buprenorphine in long-term control of chronic pain in cancer patients. Frontiers in Bioscience 2007;12:1291-9.
Pergolizzi 2008
  • Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Practice 2008;8:287-313.
Portenoy 1989
Poulain 2008
  • Poulain P, Denier W, Douma J, Hoerauf K, Samija M, Sopata M, et al. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. Journal of Pain and Symptom Management 2008;36:117-25.
Quigley 2002
Review Manager 2013
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
Robbie 1979
Sacerdote 2000
  • Sacerdote P, Bianchi M, Gaspani L, Manfredi B, Maucione A, Terno G, et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesthesia & Analgesia 2000;90:1411-4.
Sacerdote 2008
Schmidt-Hansen 2013
Seya 2011
  • Seya MJ, Gelders SF, Achara OU, Milani B, Scholten WK. A first comparison between the consumption of and the need for opioid analgesics at country, regional and global level. Journal of Pain and Palliative Care Pharmacotherapy 2011;25:6-18.
Sittl 2005
  • Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clinical Therapeutics 2005;27:225-37.
Staritz 1986
van den Beuken-van Everdingen 2007
  • van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Annals of Oncology 2007;18:1437-49.
Ventafridda 1987
WHO 1986
  • World Health Organisation (WHO). Cancer Pain Relief. 1986.
WHO 1996
  • World Health Organization. Cancer pain relief. 1996. (accessed 07 November 2013).
Wiffen 2013
World Bank 2013
  • World Bank. How we Classify Countries. (accessed 07 November 2013).

References to other published versions of this review

  1. Additional references
  2. References to other published versions of this review
Naing 2012
  • Naing C-M, Aung K, Yeoh PN. Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews 2012, Issue 1. [DOI: 10.1002/14651858.CD009596]